MarginsXMarginsX
Home › Markets › Health Care › STOK

Stoke Therapeutics Inc. (STOK)

STOK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$26.63
-0.19% on the day
Market cap
$1.7B
Small cap
Revenue · 2025
$184.4M
+404.5% on 2024
Net income · 2025
-$6.9M
-3.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1623526/000119312526108362/0001193125-26-108362-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerSTOK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001623526
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$184.4M
Net income-$6.9M
Operating income-$20.6M
Net margin-3.7%
Operating margin-11.2%
Revenue growth+404.5%
Cash$84.2M
Total assets$418.4M
P/E (computed)Net income was not positive
P/S (computed)9.4×

Warning signs

Cash runway
6.1 months
$107.3M cash at September 30, 2026
Share count, 1 year
+14.5%
2025-10-31 to 2026-10-30 · +46.5% over 3 years
Going-concern doubt
No
10-Q filed November 3, 2026
Insider net buying, 12 months
-$11.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-03
Cash and burn$107.3M cash; operating cash flow -$52.6M a quarter.Report 2026-09-30
Shares outstanding65,406,268 (2026-10-30); 57,117,150 a year earlier; 44,653,782 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-08-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United States; changed auditors 1 time in 24 months8-K 4.01 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $11.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$11.3M-$73.6M-$62.7M$107.3MNo debt tags$28.2M10-Q 2026-11-03
Q2 2026
2026-06-30
$9.3M-$61.6M-$56.6M$110.0MNo debt tags$27.6M10-Q 2026-08-03
Q1 2026
2026-03-31
$6.2M-$50.0M-$60.6M$155.7MNo debt tags$32.1M10-Q 2026-05-07
Q4 2025
2025-12-31
$1.4M-$57.9M-$30.5M$84.2MNo debt tags$184.4M10-K 2026-03-16
Q3 2025
2025-09-30
$10.6M-$38.3M-$30.4M$83.4MNo debt tags$205.6M10-Q 2026-11-03
Q2 2025
2025-06-30
$13.8M-$23.5M-$25.4M$101.5MNo debt tags$199.9M10-Q 2026-08-03
Q1 2025
2025-03-31
$158.6M$112.9M$131.8M$274.8MNo debt tags$190.9M10-Q 2026-05-07
Q4 2024
2024-12-31
$22.6M-$10.5M-$23.2M$128.0MNo debt tags$36.6M10-K 2026-03-16

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-03
Latest annual report10-K2026-03-16
Latest quarterly / interim10-Q2026-11-03
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-22

Source: SEC EDGAR submissions feed, 636 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+0.5%
1 month+18.6%
3 months-14.8%
Year to date-15.9%
1 year+2.3%
From 52-week high-30.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BRVEBraveheart Bio Inc.$19.49-0.66%$1.8B
AGIOAgios Pharmaceuticals Inc.$30.15-4.56%$1.8B
ZYMEZymeworks Inc.$26.45+0.80%$1.8B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
KLRAKailera Therapeutics Inc.$12.57-5.28%$1.6B
SRPTSarepta Therapeutics Inc. Common Stock (DE)$15.13-5.85%$1.6B
RAREUltragenyx Pharmaceutical Inc.$15.90-1.12%$1.6B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier